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Down syndrome is a complex genetic and metabolic disorder attributed to the presence of three copies of chro-
mosome 21. The extra chromosome derives from the mother in 93% of cases and is due to abnormal chromosome
segregation during meiosis (nondisjunction). Except for advanced age at conception, maternal risk factors formeiotic
nondisjunction are not well established. A recent preliminary study suggested that abnormal folate metabolism and
the 677CrT polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene may be maternal risk factors
for Down syndrome. The present study was undertaken with a larger sample size to determine whether theMTHFR
677CrT polymorphism was associated with increased risk of having a child with Down syndrome. Methionine
synthase reductase (MTRR) is another enzyme essential for normal folate metabolism. A common polymorphism
in this gene was recently associated with increased risk of neural tube defects and might also contribute to increased
risk for Down syndrome. The frequencies of the MTHFR 677CrT and MTRR 66ArG mutations were evaluated
in DNA samples from 157 mothers of children with Down syndrome and 144 control mothers. Odds ratios were
calculated for each genotype separately and for potential gene-gene interactions. The results are consistent with
the preliminary observation that the MTHFR 677CrT polymorphism is more prevalent among mothers of children
with Down syndrome than among control mothers, with an odds ratio of 1.91 (95% confidence interval [CI]
1.19–3.05). In addition, the homozygous MTRR 66ArG polymorphism was independently associated with a 2.57-
fold increase in estimated risk (95% CI 1.33–4.99). The combined presence of both polymorphisms was associated
with a greater risk of Down syndrome than was the presence of either alone, with an odds ratio of 4.08 (95% CI
1.94–8.56). The two polymorphisms appear to act without a multiplicative interaction.
Introduction
Trisomy 21, or Down syndrome, is the most common
genetic cause of human mental retardation, with an in-
cidence of ∼1/600–1,000 live births (Smith and Berg
1976). In addition, trisomy 21 is a major cause of pre-
mature pregnancy failure. It is estimated that 1/150 con-
ceptions have trisomy 21 and that 80% of these are lost
during early pregnancy (Boue et al. 1975; Hassold and
Jacobs 1984; Freeman et al. 1991). The nondisjunction
event that results in two copies of chromosome 21 takes
place in anaphase of meiosis I, during oocyte maturation
before ovulation, and/or in anaphase of meiosis II,
around the time of fertilization in the adult female (Le-
maire-Adkins et al. 1997; Picton et al. 1998; Hunt and
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Lemaire-Adkins 2000). Despite the prevalence and
health consequences of Down syndrome, the biochem-
ical and molecular basis for meiotic nondisjunction is
not understood.
Folic acid is essential for the de novo synthesis of
nucleotide precursors for normal DNA synthesis and is
also essential for normal cellular methylation reactions.
Chronic folate/methyl deficiency in vivo and in vitro has
been associated with abnormal DNA methylation (Bal-
aghi and Wagner 1993; Pogribny et al. 1995; Fowler et
al. 1998; Jacob et al. 1998), DNA strand breaks (Blount
et al. 1997; Pogribny et al. 1997; Duthie 1999), altered
chromosome recombination (Knuutila et al. 1978;
MacGregor et al. 1997), and aberrant chromosome seg-
regation (Libbus et al. 1990; Leyton et al. 1995; Chen
et al. 1998b; Titenko-Holland et al. 1998; Xu et al.
1999) On the basis of this evidence, James et al. (1999)
suggested the possibility that gene-nutrient interactions
associated with abnormal folate metabolism and DNA
hypomethylation might increase the risk of chromo-
some nondisjunction. In this preliminary study, mothers
of children with Down syndrome were found to have
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Figure 1 Overview of the interactive and interdependent reactions involved in cellular one-carbon metabolism, with emphasis on the two
major functions of these pathways in DNA metabolism: normal DNA synthesis and normal DNA methylation. These two major functions
intersect at the folate/B12–dependent methionine synthase reaction, which generates metabolically active tetrahydrofolate for DNA nucleotide
precursor synthesis, and, at the same time, regenerates methionine from homocysteine. Both DNA synthesis and DNA methylation are negatively
affected by inadequate folate or B12 intake and/or by mutations in these pathways. Note that an elevation in homocysteine induces the reversal
of the SAH hydrolase reaction and causes an elevation in SAH, a potent product inhibitor of the DNA methyltransferase reaction (De Cabo
et al. 1995).
mildly elevated plasma homocysteine levels and a 2.6-
fold increased frequency of the 677CrT polymorphism
in the methylenetetrahydrofolate reductase (MTHFR)
gene, compared with control mothers (95% CI
1.2–5.8). The data from this study further suggested
that polymorphisms in other genes in the folate pathway
may increase the risk of having a child with Down syn-
drome (James et al. 1999; Rosenblatt 1999).
MTHFR catalyzes the synthesis of 5-methyltetrahy-
drofolate, the methyl donor for the B12-dependent re-
methylation of homocysteine to methionine via the me-
thionine synthase reaction (fig. 1). Methionine is the
precursor for the synthesis of S-adenosylmethionine
(SAM), the major cellular methyl donor for DNA, RNA,
protein, and phospholipid methylation. The reduc-
tion in enzyme activity associated with the 677CrT
MTHFR polymorphism raises the dietary requirement
for folic acid to maintain normal remethylation of ho-
mocysteine to methionine (Bailey and Gregory 1999).
Consequently, low folate status in individuals with the
MTHFR polymorphism results in an increase in hom-
ocysteine and a decrease in methionine levels. Chronic
elevation in intracellular homocysteine can lead to a
decrease in the ratio of SAM to S-adenosylhomocysteine
(SAH) that is associated with inhibition of the DNA
methyltransferase and DNA hypomethylation (Balaghi
and Wagner 1993; De Cabo et al. 1995; Melnyk et al.
2000) Methionine synthase reductase (MTRR) is a re-
lated flavoprotein that maintains the methionine syn-
thase enzyme in an active state for the remethylation of
homocysteine to methionine. The cloning of the cDNA
for MTRR led to the identification of a polymorphism,
66ArG, that was recently associated with increased risk
for spina bifida (LeClerc et al. 1998; Wilson et al. 1999).
Because of the importance of the methionine synthase
reaction in maintaining normal folate metabolism and
DNA methylation, we hypothesized that this polymor-
phism could be a second maternal genetic risk factor
for Down syndrome.
The association between folate deficiency and DNA
hypomethylation suggests that genetic and/or nutri-
tional deficiencies that negatively affect folate metab-
olism may be mechanistically related to increased risk
of nondisjunction and Down syndrome. In the present
study, we have extended the initial work of James et al.
with an analysis of the association between the MTHFR
677CrT polymorphism and the maternal risk of Down
syndrome in a larger study population, and we have
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evaluated, for the first time, the association between the
MTRR 66ArG polymorphism and Down syndrome
risk.
Subjects and Methods
Study Population
Blood samples from women who had a pregnancy
affected by karyotypically confirmed full trisomy 21
(case mothers) were obtained from three study sites: met-
ropolitan Atlanta, California, and the National Center
for Toxicological Research (NCTR) in Jefferson, Ar-
kansas. For the purposes of our analyses, case and con-
trol mothers were limited to whites, to reduce the ethnic
variation between groups. Of 157 case mothers, 77 were
derived from a population-based case-control study of
trisomy 21 in the five-county area of metropolitan At-
lanta. Mothers of live-born infants with trisomy 21 were
ascertained with the assistance of the Metropolitan At-
lanta Congenital Defects Program of the Centers for Dis-
ease Control from 1989 to 1998; details regarding the
methods and sources have been described elsewhere (Ed-
monds and Oakley 1981). An additional 23 case moth-
ers were also ascertained from the California Birth De-
fects Monitoring System, which is an active birth
defects–surveillance program covering counties that in-
clude more than half of the births in California. Case
mothers were identified at genetic laboratories that rec-
ord all abnormal karyotypes of live births in the mon-
itored counties (Torfs and Christianson 1999). Recruit-
ment of mothers participating in the NCTR study was
done through Down syndrome support-group newslet-
ters and the Internet; thus, this population (57/157 case
mothers) was geographically diverse, representing 16
states and Canada (James et al. 1999). Each case mother
was asked to recruit a control mother who was ap-
proximately the same age, who resided in the same ge-
ographic area (with a similar socioeconomic status), and
who had experienced no miscarriages or abnormal preg-
nancies (46/140 control mothers). In addition, 94 con-
trol mothers were recruited through the Pediatric Test
Centre at Montreal Children’s Hospital, from a previous
case-control study (Christensen et al. 1999; Wilson et
al. 1999). Informed consent was obtained from all
participants.
Specimen Collection and Genotype Analyses
Genomic DNA was isolated from lymphocytes in
whole blood, by use of standard chloroform/phenol ex-
traction, and was stored at 20C until the genotype
analysis was performed. DNA samples obtained from
case and control mothers were analyzed at NCTR for
the MTHFR genotype and at the Montreal Children’s
Hospital Research Institute for the MTRR genotype. For
both polymorphisms, genotyping was done by PCR fol-
lowed by appropriate restriction enzyme digestion and
has been described in detail elsewhere (James et al. 1999;
Wilson et al. 1999). Laboratory personnel who per-
formed the genotyping were unaware of whether the
samples came from case or control mothers.
Statistical Analyses
Allele frequencies were calculated for each genotype,
and the differences in allele frequencies between case and
control mothers were determined using a Pearson x2 test.
Expected genotype frequencies were calculated from the
allele frequencies under the assumption of Hardy-Wein-
berg equilibrium. Odds ratios for both the heterozygous
and homozygous mutant genotypes, as compared with
the wild types, were calculated as a measure of the as-
sociation between the MTHFR and MTRR genotype
and a Down syndrome–affected pregnancy. These odds
ratios were used as an estimate of relative risk. The in-
teraction between the two genotypes was evaluated by
calculation of the odds ratio for the exposure genotype
of either MTHFR or MTRR, while the other was con-
trolled for, followed by calculation of the odds ratio for
the presence of both genotypes compared with the ab-
sence of both. For analysis of gene-gene interactions, the
MTRR homozygous AA genotype and the heterozygous
AG genotypes were combined because neither genotype
was associated with increased risk of neural tube defects
(Wilson et al. 1999) or of Down syndrome. For
MTHFR, the heterozygous CT and homozygous TT gen-
otypes were combined for the gene-gene interaction
analysis, because both genotypes reduce MTHFR en-
zyme activity and because both have been associated
with an increased risk of neural tube defects (Ou et al.
1996) and Down syndrome (James et al. 1999).
Throughout, a two-tailed P value of .05 was interpreted
as indicating a statistically significant difference. All sta-
tistical analyses were done with SAS software, version
8 (SAS Institute).
Results
Allele Frequencies
The distribution of the MTHFR genotypes in the con-
trol population was found to be in Hardy-Weinberg
equilibrium. Table 1 indicates the MTHFR and MTRR
allele frequencies for women with pregnancies affected
by Down syndrome and for control women, using the
combined data from the three sources. The frequencies
of the MTHFR 677T allele and the MTRR 66G allele
were both significantly higher among case mothers than
among control mothers. The MTHFR mutant allele fre-
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Table 1
Allele Frequencies of MTHFR 677CrT and MTRR 66ArG in
Women with Down Syndrome–Affected Pregnancies (Case
Mothers) and Control Mothers
GENOTYPE ALLELE
FREQUENCY IN MOTHERS
x2 P
Case Control
Alleles % Alleles %
MTHFR C 186 .59 193 .69
T 128 .41 87 .31 6.02 .01
MTRR A 116 .40 146 .53
G 174 .60 132 .47 8.95 .003
Table 2
Association between Maternal MTHFR Genotype and Down
Syndrome–Affected Pregnancies (Case Mothers) and Control
Mothers
Genotype
No. (%)
of Case
Mothers
(n p 157)
No. (%)
of Control
Mothers
(n p 140)
Odds
Ratio 95% CI P
CC 51 (32) 67 (48) 1.0
CT 84 (54) 59 (42) 1.87 1.14–3.06 .02
TT 22 (14) 14 (10) 2.06 .96–4.43 .09
CT or TT 106 (68) 73 (52) 1.91 1.19–3.05 .01
quency was .41 (128/314 alleles) among the case moth-
ers and .31 (87/280 alleles) among the control mothers
( ). The mean distribution of the T allele frequencyP ! .01
in the combined control group was .31, which is in the
range of that recently reported in a meta-analysis of
several studies of North American whites (Botto and
Yang 2000). For the MTRR gene, the mutant allele fre-
quency was .60 (174/290 alleles) among case mothers,
compared with .47 (132/278 alleles) among the control
mothers ( ). These data confirm that, in the cur-P ! .003
rent study population, the mutant allele frequencies for
both MTHFR and MTRR genes are significantly higher
among case mothers than among control mothers.
Maternal MTHFR Genotype and Risk of Down
Syndrome
The composite data in table 2 show that the frequen-
cies of the CC, CT, and TT genotypes among all control
mothers were 48% (67/140), 42% (59/140), and 10%
(14/140), respectively. The corresponding frequencies
among all case mothers were 32% (51/157), 54% (84/
157), and 14% (22/157). The presence of the 677CrT
substitution in one or both alleles was associated with
a 1.91-fold increase in the risk of having a child with
Down syndrome (95% CI 1.19–3.05). The odds ratio
for the heterozygous C/T genotype was 1.87 (95% CI
1.14–3.06), whereas for the homozygous TT genotype,
the odds ratio was 2.06 (95% CI 0.96–4.43). Analysis
of the combined samples from the Atlanta and California
populations, without the previously reported NCTR
data, yielded an odds ratio of 1.63 (95% CI 0.91–2.90)
for the CT and TT mutant genotypes.
Maternal MTRR Genotype and Risk of Down
Syndrome
In table 3, the distribution of MTRR genotypes in the
control population was 28% (39/139), for the homo-
zygous wild type, 49% (68/139) for the heterozygous
genotype, and 23% (32/139) for the homozygous mu-
tant genotype. The corresponding frequencies in the case
mothers were 18% (26/145) homozygous wild type,
44% (64/145) heterozygous, and 38% (55/145) ho-
mozygous mutant. Stratified by genotype, the data show
that homozygosity for the 66ArG mutation was asso-
ciated with a 2.57-fold increased risk of having a Down
syndrome–affected pregnancy (95% confidence interval
[CI] 1.33–4.99) compared with homozygous normal
subjects. The heterozygous mutation, however, was not
associated with a significant increase in risk (odds ratio
1.41; 95% CI 0.77–2.56).
Interaction between MTHFR Genotype and MTRR
Genotype
To evaluate potential gene-gene interactions, both
MTHFR and MTRR polymorphisms were evaluated in
a two-by-four table, as suggested by Botto and Mas-
troiacovo (1998). Using this approach, it was possible
to evaluate the risk associated with each genotype in-
dependently and, also, to assess the combined risk when
both polymorphisms are present. As is shown in table
4, case mothers were more likely to be heterozygous or
homozygous for the MTHFR mutant genotype and not
have the MTRR mutant GG genotype (63/145) than
were control mothers (odds ratio 2.37; 95% CI 1.31–
4.31). Case mothers who were homozygous for the
MTRR mutant polymorphism but were negative for the
MTHFR mutant allele (19/145) were at a 2.44-fold in-
creased risk (CI 1.07–5.54). The presence of both
MTHFR mutant alleles and the MTRR homozygous
mutant allele (36/145) was associated with a 4.08-fold
increased risk of having a child with Down syndrome
(95% CI 1.94–8.56). Although the presence of both
polymorphisms consistently conferred a greater risk of
Down syndrome than did the presence of either alone,
the polymorphisms appear to act without a multipli-
cative gene-gene interaction.
Discussion
Maternal age is the only well-established risk factor for
Down syndrome, and the associated risk increases ex-
ponentially at age 130 years (Hassold and Jacobs 1984).
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Table 3
Association between Maternal MTRR Genotype and Down
Syndrome–Affected Pregnancies (Case Mothers) and Control
Mothers
Genotype
No. (%)
of Case
Mothers
(n p 145)
No. (%)
of Control
Mothers
(n p 139)
Odds
Ratio 95% CI P
AA 26 (18) 39 (28) 1.0
AG 64 (44) 68 (49) 1.41 .77–2.56 .33
GG 55 (38) 32 (23) 2.57 1.33–4.99 .01
AG or GG 119 (82) 100 (72) 1.78 1.02–3.13 .06
Table 4
Interaction between MTHFR and MTRR Genotype in Women with Down
Syndrome–Affected Pregnancies (Case Mothers) and Control Mothers
MTHFR MTRR
No. (%)
of Cases
(np145)
No. (%)
of Controls
(np135) Odds Ratio 95% CI P
CC AA or AG 27 (19) 52 (39) 1.0
TT or CT AA or AG 63 (43) 51 (38) 2.37 1.31–4.31 .01
CC GG 19 (13) 15 (11) 2.44 1.07–5.54 .05
TT or CT GG 36 (25) 17 (12) 4.08 1.94–8.56 .001
It has been estimated that 15%–20% of all human con-
ceptions are chromosomally abnormal because of errors
in meiotic division; however, the majority of these errors
are embryonic lethal and result in fetal loss (Hunt 1998).
The high frequency of maternal nondisjunction is now
thought to be due to the absence of a meiotic checkpoint
in the oocyte, and this provides a plausible biological
explanation for the predominance of maternal nondis-
junction (Lemaire-Adkins et al. 1997). In the human
female, primordial oocytes enter meiosis I during fetal
development, undergo DNA replication and homolo-
gous recombination, and then remain arrested in pro-
phase I (diplotene stage) for several decades until initi-
ation of oocyte maturation and ovulation in the adult
female (Hunt and Lemaire-Adkins 2000)
Recent preliminary studies have implicated the
MTHFR 677CrT polymorphism (James et al. 1999)
and excessive smoking (Yang et al. 1999) as maternal
risk factors for Down syndrome. Interestingly, low fo-
late status has been associated with each of these po-
tential risk factors (Piyathilake et al. 1994; Lewis et al.
1998; James et al. 1999). A recent clinical study has
more directly implicated folate deficiency as a risk factor
for human aneuploidy. Lymphocytes from women con-
suming a controlled folate-deficient diet were found to
have a significantly increased frequency of kinetochore-
positive micronuclei, which are surrogate markers for
abnormal chromosome segregation (Titenko-Holland et
al. 1998). Folate supplementation after the folate-de-
pletion phase in this metabolic study was associated
with a significant decrease in these centromeric frag-
ments. Taken together, these studies support the pos-
sibility that multifactorial gene-environment interac-
tions that compromise maternal folate status may
promote meiotic nondisjunction and the risk of a Down
syndrome conception.
The results of the present study indicate that the si-
multaneous presence of the MTHFR 677T polymor-
phism and the homozygous MTRR 66G polymorphism
conferred a four-fold increase in the maternal risk of
having a child with Down syndrome (95% CI
1.94–8.56). In the combined populations, the MTHFR
677T substitution in one or both alleles was associated
with a 1.9-fold increase in risk (95% CI 1.19–3.05),
and the presence of the homozygous 66G allele in
MTRR was associated with a 2.57-fold increase in risk
(95% CI 1.33–4.99). The odds ratio for the mutant
677T allele in the Atlanta and California cohorts did
not quite reach statistical significance when analyzed
independently from that in the NCTR cohort; however,
the point estimate remained 11, indicating increased risk
(odds ratio 1.63; 95% CI 0.91–2.90).
A frequent challenge in conducting studies of gene-
gene interactions is balancing the need for relatively
large study populations against the need to minimize
bias that may occur because of population admixture.
To acquire sufficient statistical power, case mothers in
the present study were drawn from two birth defect
registries and from a volunteer sample that included
case mothers from 16 states and Canada. Control moth-
ers were limited to women who were documented to
have no children with birth defects and were pooled
from two previous studies. To minimize ethnic bias, all
participants were restricted to North American whites.
Because genotypes from appropriate control mothers
were not available from the Atlanta and California reg-
istries, control samples from the NCTR study and from
a previous study of NTDs in Montreal were combined.
Thus, an inherent limitation of the current study is the
potential bias of population admixture introduced by
pooling control mothers from geographical areas dif-
ferent from those that provided the case mothers. To
determine whether our pooled control population was
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a representative North American sample, we compared
our control MTHFR 677T allele frequencies with those
of a recently published meta-analysis of North Ameri-
can whites (Botto and Yang 2000). The MTHFR 677T
allele frequency in our control group was .31, which
was within the range of frequencies reported in the
meta-analysis. We had more difficulty evaluating po-
tential bias in the association between MTRR and
Down syndrome, since there are no published data on
allele frequencies or genotype distribution outside of our
study sites. Thus, we compared the genotype distribu-
tion among our control mothers with that among fa-
thers from the Atlanta and California samples, who may
be more ethnically similar to the case mothers than were
a convenience sample of control mothers. The frequency
of MTRR 66ArG homozygosity was 24.2% among the
fathers and 23.0% among the control mothers. Taken
together, these observations suggest that our combined
control samples were representative of the MTHFR al-
lele frequencies and MTRR homozygosity within North
American whites. Nonetheless, the findings of the cur-
rent study need to be confirmed in a large prospectively
designed population-based case-control study.
Because MTHFR and MTRR require folate and B12,
respectively, to support the methionine synthase reac-
tion, the metabolic impact of both polymorphisms is
magnified by low levels of folate or B12 (Bailey and
Gregory 1999; Wilson et al. 1999). Accordingly, risk
estimates that stratify mutant genotypes by nutritional
status result in more sensitive risk estimates than do
those based on genotype alone. For example, stratifi-
cation of the MTHFR 677CrT genotype by folate
status or of the MTRR 66ArG genotype by B12 status
has resulted in more sensitive risk estimates for neural
tube defects (Chen et al. 1998a; Christensen et al. 1999;
Wilson et al. 1999). The ability to analyze the MTHFR
and MTRR genotypes in terms of specific metabolic
biomarkers—such as plasma homocysteine, folate, and/
or B12 levels—would increase the power to detect a sig-
nificant impact on Down syndrome risk. A limitation
of the present study is that we did not have access to
plasma samples for evaluation of folate, B12, or hom-
ocysteine levels in case and control mothers.
A compromise in the methionine synthase reaction
caused by genetic and/or dietary factors could promote
abnormal chromosome segregation by an indirect effect
on oocyte DNA methylation patterns and higher-order
chromatin structure. The secondary structure of peri-
centromeric heterochromatin, at repetitive satellite se-
quences, is involved in protein-DNA binding and in
cohesion between sister chromatids (Renauld and Gas-
ser 1997; Clarke 1998; Cobb et al. 1999). The abundant
methyl-binding protein, MeCP2, preferentially binds to
pericentromeric DNA in a complex with histone de-
acetylase, resulting in local histone deacetylation and
chromatin condensation (Nan et al. 1996, 1998; Jones
et al. 1998). Recent evidence linking DNA methylation
to histone deacetylation and chromatin condensation
supports the possibility that DNA methylation patterns
may be linked mechanistically to the epigenetic altera-
tions in chromatin structure required for normal chro-
mosome segregation (Bestor and Tycko 1996; Grewal
et al. 1998; Vig 1998). In nonreplicating cells, such as
oocytes, the loss of methyl groups at methylated CpG
sites in DNA can occur during excision repair (Brooks
et al. 1996), by spontaneous deamination of 5-methyl
cytosine to thymine (Gonzalgo and Jones 1997), or dur-
ing DNA strand exchange associated with recombina-
tion (Bestor and Tycko 1996). The failure of the DNA
methyltransferase to remethylate the newly synthesized
strands would result in permanent loss of DNA meth-
ylation patterns under conditions of localized folate/
methyl deficiency.
The importance of stable pericentromeric DNA meth-
ylation for normal chromosome segregation has been
underscored by several recent discoveries. For example,
lymphocytes from individuals with the rare autosomal
disorder ICF (immunodeficiency, centromeric instabil-
ity, and facial anomalies) exhibit profound chromoso-
mal abnormalities, including selective undermethylation
of pericentromeric satellite DNA, chromosome decon-
densation, and complex multiradiate chromosomes
(Miniou et al. 1997). The genetic origin of this disorder
was recently discovered to be a mutation in the de novo
DNA methyltransferase 3B (DNMT3B) and supports a
causal association between DNA hypomethylation, per-
icentromeric decondensation, and abnormal chromo-
some segregation (Hansen et al. 1999; Xu et al. 1999).
Treatment of cultured cells with 5-azacytidine, a potent
demethylating agent, similarly results in pericentromeric
decondensation and profound chromatid missegrega-
tion in anaphase (Leyton et al. 1995; Vig and Hallet
2000). Chromosomal deletions, translocations, and in-
stability were recently reported in murine embryonic
stem cells nullizygous for the major DNA methyltrans-
ferase (Dnmt1) gene (Chen et al. 1998b). Aneuploidy
and chromosomal instability are present in most human
cancers, and chromosomal instability has recently been
shown to be directly related to the extent of DNA hy-
pomethylation (Vilain et al. 1999). These data strongly
suggest that stable methylation in pericentromeric DNA
is an essential prerequisite for normal chromosome or-
ganization, stabilization, and segregation.
The association between folate deficiency and DNA
hypomethylation lends support to the possibility that
the increased frequency of the MTHFR and MTRR
polymorphisms observed in the present study may be
associated with chromosomal nondisjunction and
Down syndrome. Further research is needed to evaluate
the paradigm suggested by the present results: an as-
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sociation between maternal folate metabolism and
Down syndrome. Additional studies of other candidate
genes in the folate pathway, as well as a systematic study
of interactions with other micronutrients involved in
folate/methyl metabolism in women with Down syn-
drome–affected pregnancies, may suggest opportunities
to improve public health strategies for the primary pre-
vention of Down syndrome.
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